Invivyd Inc. reports Q3 net product revenue of $13.1 million

Reuters

2025/11/06

Invivyd Inc. reports Q3 net product revenue of $13.1 million

Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581062092"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581062092\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581062092?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062092","market":"nz","top_or_hot":-1,"title":"Invivyd Inc. reports Q3 net product revenue of $13.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Invivyd Inc. reports Q3 net product revenue of $13.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvivyd Inc. reports Q3 net product revenue of $13.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVVD","symbol_name":"Invivyd, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLbLZKJp:1","article_id":"2581062092","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062092","pubTimestamp":1762431084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA  in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVVD":"Invivyd, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Invivyd Inc.报告第三季度产品净收入为1310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVVD":0.9},"content_text":"Invivyd Inc. reports Q3 net product revenue of $13.1 million\n    \n\n        Invivyd Inc. reported net product revenue of $13.1 million for PEMGARDA (pemivibart) in the third quarter of 2025, reflecting a 41% year-over-year increase and 11% growth compared to the previous quarter. The company ended the third quarter of 2025 with $85.0 million in cash and cash equivalents, and over $100 million by the end of October 2025. Invivyd completed a public offering in August 2025, raising approximately $57.5 million in gross proceeds, and generated an additional $29.8 million through an at-the-market offering facility in October 2025. Business developments during the period included the U.S. IND clearance and FDA alignment for the VYD2311 pivotal clinical program, expanded commercial activity for PEMGARDA among healthcare providers treating immunocompromised patients, new leadership appointments, and the formation of the SPEAR Study Group to assess monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-268057), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}